On Jan. 05, Brockstedt Dirk G. divested U.S. $39,428 in shares of RAPT Therapeutics Inc.. The Chief Scientific Officer sold 2,000 shares at a price per share of $19.71. The transaction decreased this specific insider’s holdings to 17,556 shares worth around $0.36 million at present.
H.C. Wainwright launched its RAPT Therapeutics Inc. [RAPT] rating to the equivalent of a Buy and assigned the price target of $40, in a research note dated June 01, 2020. That figure represents around a 48.62% premium from where the company’s shares closed on Wednesday. Some new analysts also started their coverage, with H.C. Wainwright’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in early June. Meanwhile, Cantor Fitzgerald had launched its coverage on RAPT with “an Overweight”, in a research note produced for clients May 19, 2020. In addition, there was a new coverage from ROTH Capital on April 13, 2020. The research firm rated RAPT “a Buy”.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Is RAPT Therapeutics Inc. [NASDAQ:RAPT] a Good Buy Right Now?
It should be noted that RAPT technical indicators for short, intermediate as well as long term progress have placed an overall average of 88% as Sell. The average signal changed from 72% Sell in the last week and compares with 24% Sell in the past month. Data from RAPT Therapeutics Inc.’s Trend Spotter indicated that the signals were Weakest. The stock current average is 0.32 million shares in the past 20 days and the short term average signal indicates a 100% Sell. In the last 50 days, the average trading volume was 0.51 million shares while the medium term average advocated for 100% Sell. The average long-term signal stands at 50% Sell and the 100-day average volume stands at 0.38 million shares.
RAPT Price Performance
On Wall Street, RAPT Therapeutics Inc. [NASDAQ:RAPT] finished Wednesday’s session up 4.31% at $20.55. The stock went up to $21.01 at the same session while its lowest single day price was $19.41. In the last five days, it saw a rise of about 3.16%, RAPT Therapeutics Inc. shares gained by almost 4.05% since the beginning of the year. However, the share price has dropped to as low as -59.87% below its one year high. On 01/06/21, the company shares recorded $21.01, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $19.14. The company’s shares have declined by -33.50% in the past year. The 50-day SMA achieved is $23.94 while the 200-day SMA is $24.53. Volume gained to 0.34 million from 0.2 million in the previous session.
RAPT Therapeutics Inc. [RAPT] Valuation Measures
Notably, RAPT Therapeutics Inc. [RAPT] stock can be helpful for investors to consider historical price-sales ratio, more specifically, a 131.19 PS value ratio is reported for the last one year of reported earnings. That is higher than the industry average of 20.33.
RAPT Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 19.64 level, and in case of violation of this particular level, it will cause more drop to 18.72 level. On the upper level, 21.92 is still the key resistance. The stock may increase to the subsequent resistance at 21.24. The Relative Strength Index (RSI) pinned on the 14-day chart is 43.39, implying a neutral technical stance while the MACD stands at -1.20, meaning price will decrease in the next trading period. Percent R indicator moved to 70.50%, implying bearish price movement. Stochastic %K at 23.01% suggest holding the stock.
What is the short interest in RAPT Therapeutics Inc.?
Short interest in the RAPT Therapeutics Inc. stock has plunged, decreasing by -0.68 million shares to total 1.03 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 0.35 million, data from Yahoo Finance shows. The increase of 66.47% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 9.25% of the overall float for the stock.
RAPT Therapeutics Inc.’s Biggest Shareholders: Who Owns RAPT Therapeutics Inc. [RAPT]?
Filings by T. Rowe Price Associates, Inc. showed that the firm now holds a total of 2,628,020 shares or roughly 10.70% of the outstanding RAPT shares. This means their shares have increased by 1,197,107 from the 2,628,020 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, Wellington Management Co. LLP updated stake is worth $34,599,557. Details in the latest 13F filings reveal that Regents of the University of Cali disposed off their -12.18% stake valued at $29,919,856. During the last quarter, Regents of the University of Cali liquidated -191,533 of its shares in RAPT Therapeutics Inc. while Perceptive Advisors LLC bought 1,327,481 shares. The BlackRock Fund Advisors’s holdings currently number 656,750 shares at $13496212.5. According to the firm’s last 13F report, Avoro Capital Advisor LLC shares in the company at filing stood at 575,000 shares, roughly $12,460,250.
RAPT Earnings Forecast For The Current Quarter
RAPT Therapeutics Inc. [RAPT] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $1.28M and an earnings per share of -$0.59 for Dec 2020. Looking further ahead, the company is expected to report revenue of $980k at an EPS of -$0.62 for Mar 2021. The estimates represent -61.40% and -21.00% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
What are analyst thoughts on RAPT Therapeutics Inc.?
Looking forward to the RAPT Therapeutics Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for RAPT Therapeutics Inc. stock at $34.00 within the next 12 months, which represents almost 39.56 per cent growth from its previous closing price of $20.55. The highest analysts’ target for RAPT Therapeutics Inc. stock projections is $51.00 and the lowest one is $23.00. Still, 6 analysts sharing their consensus rating for RAPT stock in 2021 agree that it is a Buy.